Yahoo · Aug 26, 2026
Ambu AS (AMBFF) (Q3 2026) Earnings Call Highlights: Strong Endoscopy Growth and Margin ...
Ambu AS (AMBFF) delivers 16% organic growth in endoscopy solutions and improved EBIT margin, while navigating FX and tariff challenges.
OTC · AMBBY
Healthcare · Medical - Devices
$11.00
Up+$0.00 (+0.00%)
Updated Sep 13, 2026, 5:23 PM
SID Score
4.8/10
Composite research score
Smart Money
46/100
Neutral
Price performance
1M range · 0 trading sessions · Daily adjusted prices
AMBBY does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning AMBBY.
AMBBY research
Company profile and research snapshot.
AMBU A S UNSP/ADR
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 8, 2026 | ROTHSCHILD & CO REDBURN | Neutral | — |
| Jul 7, 2026 | DNB CARNEGIE | Buy | — |
| Feb 5, 2026 | ROTHSCHILD & CO REDBURN | Neutral | — |
| Feb 5, 2026 | DNB CARNEGIE | Buy | — |
| Jan 27, 2026 | ROTHSCHILD & CO REDBURN | Neutral | — |
No generated briefing is available yet.
Yahoo · Aug 26, 2026
Ambu AS (AMBFF) delivers 16% organic growth in endoscopy solutions and improved EBIT margin, while navigating FX and tariff challenges.
SeekingAlpha · Aug 26, 2026
Ambu A/S (AMBBY) Q3 2026 Earnings Call August 26, 2026 5:00 AM EDTCompany ParticipantsBritt Jensen - Chief Executive OfficerHenrik Bender - Chief Financial...
SeekingAlpha · Aug 26, 2026
2026-08-26. The following slide deck was published by Ambu A/S in conjunction with their 2026 Q3 earnings call.
SeekingAlpha · Feb 4, 2026
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.


The latest Smart Investors Daily articles mentioning AMBBY.
No results
No recent SID articles mention AMBBY.